Loading clinical trials...
Loading clinical trials...
MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A randomized (1:1), placebo-controlled, double-blind, parallel group trial will be carried out to assess ld-IL-2 safety and clin...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
NCT07294144 · ALS (Amyotrophic Lateral Sclerosis)
NCT07571174 · Amyotrophic Lateral Sclerosis
NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more
NCT07660614 · Amyotrophic Lateral Sclerosis
NCT07369076 · Amyotrophic Lateral Sclerosis (ALS)
CHRU de Lille - Hôpital Roger Salengro
Lille
CHU de Limoges - Hôpital Dupuytren
Limoges
HCL - Hôpital Neurologique P. Wertheimer
Lyon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions